Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-631 in Healthy Adult Volunteers
NCT07069036Phase 1Completed
- Sponsor
- Septerna
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SEP-631 (3 arms), sponsored by Septerna. Primary endpoint: Frequency of treatment emergent adverse events. Started Jul 2025; status: completed.
02
Drugs
SEP-631
Beyond the preview
Go deeper on NCT07069036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069036.